166 related articles for article (PubMed ID: 32295687)
1. Simulation-based comparison of Biopharmaceutics Classification System and drug structure.
Chen T; Wu T; Li N; Jiang Y; Yin H; Wu M
Pharmazie; 2020 Apr; 75(4):124-130. PubMed ID: 32295687
[No Abstract] [Full Text] [Related]
2. The Biopharmaceutics Classification System: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC.
Tsume Y; Mudie DM; Langguth P; Amidon GE; Amidon GL
Eur J Pharm Sci; 2014 Jun; 57():152-63. PubMed ID: 24486482
[TBL] [Abstract][Full Text] [Related]
3. Is the full potential of the biopharmaceutics classification system reached?
Bergström CA; Andersson SB; Fagerberg JH; Ragnarsson G; Lindahl A
Eur J Pharm Sci; 2014 Jun; 57():224-31. PubMed ID: 24075971
[TBL] [Abstract][Full Text] [Related]
4. A non-binary biopharmaceutical classification of drugs: the ABΓ system.
Macheras P; Karalis V
Int J Pharm; 2014 Apr; 464(1-2):85-90. PubMed ID: 24456673
[TBL] [Abstract][Full Text] [Related]
5. Elucidating the role of dose in the biopharmaceutics classification of drugs: the concepts of critical dose, effective in vivo solubility, and dose-dependent BCS.
Charkoftaki G; Dokoumetzidis A; Valsami G; Macheras P
Pharm Res; 2012 Nov; 29(11):3188-98. PubMed ID: 22760660
[TBL] [Abstract][Full Text] [Related]
6. A comparative analysis of biopharmaceutics classification system and biopharmaceutics drug disposition classification system: a cross-sectional survey with 500 bioequivalence studies.
Cristofoletti R; Chiann C; Dressman JB; Storpirtis S
J Pharm Sci; 2013 Sep; 102(9):3136-44. PubMed ID: 23580377
[TBL] [Abstract][Full Text] [Related]
7. Forecasting oral absorption across biopharmaceutics classification system classes with physiologically based pharmacokinetic models.
Hansmann S; Darwich A; Margolskee A; Aarons L; Dressman J
J Pharm Pharmacol; 2016 Dec; 68(12):1501-1515. PubMed ID: 27781273
[TBL] [Abstract][Full Text] [Related]
8. Very rapid dissolution is not needed to guarantee bioequivalence for biopharmaceutics classification system (BCS) I drugs.
Kortejärvi H; Shawahna R; Koski A; Malkki J; Ojala K; Yliperttula M
J Pharm Sci; 2010 Feb; 99(2):621-5. PubMed ID: 19844950
[TBL] [Abstract][Full Text] [Related]
9. Provisional classification and in silico study of biopharmaceutical system based on caco-2 cell permeability and dose number.
Pham-The H; Garrigues T; Bermejo M; González-Álvarez I; Monteagudo MC; Cabrera-Pérez MÁ
Mol Pharm; 2013 Jun; 10(6):2445-61. PubMed ID: 23675957
[TBL] [Abstract][Full Text] [Related]
10. Solubility Determination of Active Pharmaceutical Ingredients Which Have Been Recently Added to the List of Essential Medicines in the Context of the Biopharmaceutics Classification System-Biowaiver.
Plöger GF; Hofsäss MA; Dressman JB
J Pharm Sci; 2018 Jun; 107(6):1478-1488. PubMed ID: 29421214
[TBL] [Abstract][Full Text] [Related]
11. Comparing multilabel classification methods for provisional biopharmaceutics class prediction.
Newby D; Freitas AA; Ghafourian T
Mol Pharm; 2015 Jan; 12(1):87-102. PubMed ID: 25397721
[TBL] [Abstract][Full Text] [Related]
12. Biopharmaceutics classification systems for new molecular entities (BCS-NMEs) and marketed drugs (BCS-MD): theoretical basis and practical examples.
Papadopoulou V; Valsami G; Dokoumetzidis A; Macheras P
Int J Pharm; 2008 Sep; 361(1-2):70-7. PubMed ID: 18614303
[TBL] [Abstract][Full Text] [Related]
13. pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery.
Varma MV; Gardner I; Steyn SJ; Nkansah P; Rotter CJ; Whitney-Pickett C; Zhang H; Di L; Cram M; Fenner KS; El-Kattan AF
Mol Pharm; 2012 May; 9(5):1199-212. PubMed ID: 22489626
[TBL] [Abstract][Full Text] [Related]
14. Provisional in-silico biopharmaceutics classification (BCS) to guide oral drug product development.
Wolk O; Agbaria R; Dahan A
Drug Des Devel Ther; 2014; 8():1563-75. PubMed ID: 25284986
[TBL] [Abstract][Full Text] [Related]
15. A Refined Developability Classification System.
Rosenberger J; Butler J; Dressman J
J Pharm Sci; 2018 Aug; 107(8):2020-2032. PubMed ID: 29665381
[TBL] [Abstract][Full Text] [Related]
16. The role of BCS (biopharmaceutics classification system) and BDDCS (biopharmaceutics drug disposition classification system) in drug development.
Benet LZ
J Pharm Sci; 2013 Jan; 102(1):34-42. PubMed ID: 23147500
[TBL] [Abstract][Full Text] [Related]
17. Prediction of solubility and permeability class membership: provisional BCS classification of the world's top oral drugs.
Dahan A; Miller JM; Amidon GL
AAPS J; 2009 Dec; 11(4):740-6. PubMed ID: 19876745
[TBL] [Abstract][Full Text] [Related]
18. [Biopharmaceutical classification system--experimental model of the prediction of drug bioavailability].
Golovenko NIa; Borisiuk IIu
Biomed Khim; 2008; 54(4):392-407. PubMed ID: 18988456
[TBL] [Abstract][Full Text] [Related]
19. The Biopharmaceutics Classification System (BCS) and the Biopharmaceutics Drug Disposition Classification System (BDDCS): Beyond guidelines.
Charalabidis A; Sfouni M; Bergström C; Macheras P
Int J Pharm; 2019 Jul; 566():264-281. PubMed ID: 31108154
[TBL] [Abstract][Full Text] [Related]
20. Oral biopharmaceutics tools - time for a new initiative - an introduction to the IMI project OrBiTo.
Lennernäs H; Aarons L; Augustijns P; Beato S; Bolger M; Box K; Brewster M; Butler J; Dressman J; Holm R; Julia Frank K; Kendall R; Langguth P; Sydor J; Lindahl A; McAllister M; Muenster U; Müllertz A; Ojala K; Pepin X; Reppas C; Rostami-Hodjegan A; Verwei M; Weitschies W; Wilson C; Karlsson C; Abrahamsson B
Eur J Pharm Sci; 2014 Jun; 57():292-9. PubMed ID: 24189462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]